Pfizer, BioNTech COVID Vaccine Wins European Backing

December 22, 2020by Naomi Kresge and Suzi Ring, Bloomberg News (TNS)
Numbered inoculation cabins stand at the completed Covid-19 vaccination center at the Arena Berlin events venue during a visit by Federal President Frank-Walter Steinmeier on December 21, 2020 in Berlin, Germany. The vaccination center is one of six in Berlin and will likely begin offering inoculations beginning early January. The first vaccinations in Germany will likely begin December 27 with mobile teams inoculating staff and residents at nursing homes for senior citizens. (Christian Marquardt-Pool/Getty Images/TNS)

Pfizer Inc. and BioNTech SE’s COVID-19 vaccine won the backing of the European medicines regulator, clearing the way for inoculations to start before the end of the year as the continent struggles with rising death rates and tighter lockdowns.

The endorsement of the vaccine, Comirnaty, was announced in a news briefing by the European Medicines Agency on Monday. The final step in approval is a sign-off from the European Commission, expected later today.

“It is a significant step forward in our fight against this pandemic,” Emer Cooke, executive director of the agency, said in the meeting. “This is really a historic scientific achievement.”

EMA officials said there’s no evidence to suggest the vaccine won’t work against the new variant of the coronavirus that emerged in southeast England, leading to an emergency lockdown in London and causing countries including Canada, France and Germany to halt flights and suspend rail links.

European Union leaders pushed the regulator to speed up its review amid complaints that residents across the continent were still waiting to get a vaccine — pioneered in Germany — that is already being used in the U.K. and U.S. The goal is to start a European immunization campaign on Dec. 27, commission President Ursula von der Leyen said last week.

Monday’s recommendation puts the EU in position to meet that timeline. Von der Leyen said in a tweet that she expects the commission to act swiftly, with a decision by tonight.

The trials showed the vaccine was effective in preventing Covid-19 in people from 16 years of age, the agency said in a statement.

Just as Europe prepares to roll out the first vaccine, countries are suspending travel links to the U.K. amid an effort to contain a variant of the coronavirus that officials say is spreading quickly across London and southeast England.

Unlike the U.S. and U.K., which conducted emergency authorizations, the EMA reviewed the vaccine for a conditional marketing authorization. Such a decision requires more evidence, the EU commission’s directorate-general for health said last week. The EMA committee is also reviewing a similar vaccine from Moderna Inc., with a key meeting set for Jan. 6.

___

©2020 Bloomberg L.P.

Distributed by Tribune Content Agency, LLC

Health

Michigan House GOP Unveils Rebuttal to Whitmer’s COVID-19 Recovery Plan
State News
Michigan House GOP Unveils Rebuttal to Whitmer’s COVID-19 Recovery Plan
January 27, 2021
by Reece Nations

LANSING, Mich. — Michigan House Appropriations Committee Chairman Thomas Albert announced Republicans’ rebuttal to Gov. Gretchen Whitmer’s proposed COVID-19 recovery plan.  The House Republicans’ plan would provide roughly $3.5 billion in federal and state funds for employers, families, schools and vaccine distribution, according to a statement... Read More

Merck Halts Work on Vaccine, Moderna Delivers 30.4 Million Doses to Feds
Business
Merck Halts Work on Vaccine, Moderna Delivers 30.4 Million Doses to Feds
January 27, 2021
by Daniel Mollenkamp

Merck has withdrawn from the sprint to produce coronavirus vaccines after its two candidates failed to achieve strong results in preliminary trials. The first phase of clinical studies showed that even though the vaccine candidates were "well tolerated" the immune responses triggered by them were "inferior"... Read More

Biden Says He's ‘Bringing Back the Pros’ for Virus Briefings
Health
Biden Says He's ‘Bringing Back the Pros’ for Virus Briefings

WASHINGTON (AP) — For nearly a year it was the Trump show. Now President Joe Biden is calling up the nation’s top scientists and public health experts to regularly brief the American public about the pandemic that has claimed more than 425,000 U.S. lives. Beginning Wednesday, administration experts... Read More

US Boosting Vaccine Deliveries Amid Complaints of Shortages
State News
US Boosting Vaccine Deliveries Amid Complaints of Shortages

Answering growing frustration over vaccine shortages, President Joe Biden announced that the U.S. is ramping up deliveries to hard-pressed states over the next three weeks and expects to provide enough doses to vaccinate 300 million Americans by the end of the summer or early fall. Biden,... Read More

New Study Warns of COVID-19’s Negative Impact on Rural Colleges and Communities
Education
New Study Warns of COVID-19’s Negative Impact on Rural Colleges and Communities
January 26, 2021
by Sara Wilkerson

A new study published by the Alliance for Research on Regional Colleges reveals that the COVID-19 pandemic’s impact on underserved rural colleges and surrounding communities could endanger the stability of local economies, health care systems and social mobility for the foreseeable future.  The study, a research... Read More

Biden More Bullish on Vaccines, Open to 1.5M Daily Shot Goal
Health
Biden More Bullish on Vaccines, Open to 1.5M Daily Shot Goal

WASHINGTON (AP) — President Joe Biden on Monday appeared to boost his goal for coronavirus vaccinations in his first 100 days in office, suggesting the nation could soon be injecting 1.5 million shots on an average per day. Biden signaled his increasing bullishness on the pace... Read More

News From The Well
scroll top